Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis Partnering With Columbia to Study Immune Response to SARS-CoV-2

NEW YORK – Single-cell proteomics firm IsoPlexis said today that it is partnering with researchers at the Department of Medicine at Columbia University to study the immune response in COVID-19 patients.

The Branford, Connecticut-based company said it plans to use its single-cell proteomics platform to identify drivers of durable and protective immune responses to the virus, with the ultimate goal of using that information to inform therapeutics development.

"We are looking forward to our partnership with Columbia University in the fight against COVID-19," IsoPlexis CEO Sean Mackay said in a statement. "This work will provide critical functional insights into the mechanisms of protective and durable immune response to COVID-19, especially with regards to the activity of T cells."

Financial and other terms of the agreement were not disclosed.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.